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ABSTRACT
The treatment of articular and extra-articular manifestations associated with HLA-B27 has undergone
dramatic changes over the past two decades, mainly as a consequence of the introduction of biologic
agents and in particular anti-tumor necrosis factor α (anti-TNFα) agents. Uveitis is known to be the most
frequent extra-articular feature in HLA-B27-associated spondyloarthritides. Topical corticosteroids and
cycloplegic agents remain the cornerstones of treatment. However, biologic therapy may be effective in
the management of refractory or recurrent forms of uveitis. This review gives an update on the manage-
ment of HLA-B27-associated ocular disorders with biologics, including anti-TNFα agents and non-anti-
TNFα biologic modifier drugs. There is an emerging role for newer biologics targeting interleukin-12/23
and interleukin-17 for the treatment of spondyloarthritides but data on their efficacy on anterior uveitis are
sparse.
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Over the past two decades, the introduction of
biologic treatments, especially those targeting anti-
tumor necrosis factor α (anti-TNFα agents) has dra-
matically improved the management of rheumatic
diseases, such as rheumatoid arthritis, juvenile idio-
pathic arthritis (JIA) and the spondyloarthritides
(SpA). Anterior uveitis is the most common ocular
manifestation in patients affected by SpA. Similarly,
anti-TNFα agents have become a valuable addition
to the therapeutic armamentarium for patients with
associated uveitis that is refractory or intolerant to
conventional treatment. Conversely, only few data
are available for other biologic agents. The purpose
of this review is to summarize current evidence on
the use of these drugs, highlighting various possi-
ble choices of molecules and treatment strategies in
HLA-B27-associated ocular disorders.
HLA-B27-RELATED DISORDERS
The spondyloarthritides are a group of chronic inflam-
matory diseases characterized by typical clinical fea-
tures, such as axial inflammation, enthesitis and extra-
articular manifestations associated with the human
leucocyte antigen B27 (HLA-B27). Traditionally, the
term “spondyloarthritis (SpA)” comprises ankylosing
spondylitis (AS), reactive arthritis, psoriatic arthritis
(PsA), arthritis associated with inflammatory bowel
disease (IBD), and undifferentiated spondyloarthritis.1
The Assessment of SpondyloArthritis International
Society (ASAS) group has recently developed criteria
to classify patients with axial SpA (axSpA) with or
without radiographic sacroiliitis, and criteria to clas-
sify patients with peripheral SpA. Patients with axSpA
can in turn be classified as having ankylosing spondy-
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litis, if they have definite structural changes in their
sacroiliac joints.2 There is a strong association of SpA,
especially axSpA and AS with the major histocompat-
ibility complex (MHC) class I molecule HLA-B27,
which is now also part of the classification criteria for
axSpA.1,3,4 More than half of the patients with axSpA
have extra-articular manifestations, such as psoriasis,
IBD, and uveitis. The absence of rheumatoid factor
was the basis for the Spa group being labeled ‘serone-
gative’ – although this is no longer used.5
Anterior uveitis is the most common extra-articular
manifestation of AS.6–8 About one-third of the patients
with AS have one or more episodes of anterior uveitis.
More rarely, intermediate, posterior, or panuveitis may
develop, especially in patients with IBD.9 The typical phe-
notype of HLA-B27-associated uveitis is an acute unilat-
eral alternating non-granulomatous anterior uveitis,
characterized by significant cellular and protein extrava-
sation into the aqueous humor, including occasionally
fibrin and even hypopyon in the anterior chamber, with
high tendency for recurrences.10 Each acute episode lasts
4–6 weeks on average. The first episode most commonly
occurs between the ages of 20 and 40. The most frequent
complications are posterior synechiae, cataract, glaucoma,
and the development of chronic anterior uveitis. Sight-
threatening posterior segment complications can occur,
especially cystoid macular edema (up to 13%).11–13
Recently, secondary glaucoma was found to be the most
common primary cause for irreversible vision loss in
patients with HLA-B27-associated uveitis.14
The approach is to treat the inflammation aggressively
with topical steroids. Nevertheless, systemic treatment
with corticosteroids or other immunosuppressive agents
has a role in the more severe recurrent or chronic anterior
uveitis.15 Indeed, sulfasalazine may have a beneficial
effect in preventing relapses, even though the literature
is scarce. Thus, one retrospective study showed that treat-
ment with sulfasalazine can reduce the number of uveitis
relapses in spondyloarthritis.16 Two prospective studies
confirmed these results in patients with both spondyloar-
thritis and idiopathic acute anterior uveitis.17,18 However,
sulfasalazine is known to be effective for peripheral arthri-
tis in SpA, but there is no clear option for the axial
manifestations.19 Otherwise, the use of methotrexate in
uveitis associated with SpA is, notwithstanding, contro-
versial with little data in the literature.20,21 Besides, Kezic
et al. reported in a murine model resembling spondyloar-
thritis that interferon gamma (IFNγ) deficiency markedly
exacerbates uveitis while ameliorating joint and spine
disease, indicating divergent mechanisms that drive dis-
eases in the eye versus joints and spine. Therefore, the
clinical response to one specific treatment in one organ
does not guarantee a clinical response in another organ.22
Episcleritis and scleritis may rarely occur. Finally, reac-
tive arthritis may be associated with conjunctivitis, which
may be easily overlooked. For the purposes of this review,
we have focused on the treatment outcomes related to
HLA-B27-associated uveitis.
BIOLOGICS
Biologic agents are a class of therapeutic drugs that
target different mediators involved in the pathogenesis
of human diseases, of which the first biosimilars have
been approved by EMA (European Medicines Agency)
in 2013,23 and more recently by the FDA (Food and
Drug Administration, USA).24 Definitions of biologics
in common use vary greatly.25A proposed definition
is: “a biologic is a protein or nucleic acid based phar-
maceutical substance used for therapeutic or in vivo
diagnostic purposes, which is produced by means
other than direct extraction from a native (non-engi-
neered) biological source.”26 In inflammatory diseases,
the therapeutic target of a biologic is often a specific
protein of the immune system, related to inflammatory
processes. This has changed the management of
chronic inflammatory diseases in the sense that this
approach is much more specific, for example, by
directly and rather exclusively targeting TNFα or inter-
leukin 6. Biologics include monoclonal antibodies,
soluble receptors, cytokines themselves (such as inter-
ferons), and natural cytokine antagonists.27,28
Monoclonal antibodies can be murine, chimeric (partly
murine and human), humanized (only the comple-
mentarity determining parts of the variable regions
are of mouse-sequence origin), and fully humanized.
An international nomenclature was proposed to estab-
lish a common classification.29 The pharmaceutical com-
pany gives usually the prefix and the suffix indicating
whether the molecule is a monoclonal antibody (mab) or
a soluble receptor (cept). Concerning monoclonal antibo-
dies (mab), the classification also determines the target
and the source of production. For example, infliximab is
an anti-TNFα antibody used against cells of the immune
system (-li-), chimeric (-xi-), and monoclonal (-mab).
The management of anterior uveitis associated with
SpA covers both prevention and treatment. There is
some evidence on the efficacy of biologics, mainly anti-
TNFα agents. This review concentrates on the use of
anti-TNFα agents.
Anti-TNFα Agents and HLA-B27-associated
uveitis
Anti-TNFα
Among pro-inflammatory cytokines produced in answer
to the stimuli of the innate and adaptive immune system,
TNFα plays a key role. Indeed, TNFα is found by diverse
methods in the synovial cells of the articular liquid and the
synovial membrane it thus constitutes a target of choice to
handle the inflammation of SpA. Moreover, there are,
currently, substantial data accumulated on the anti-
TNFα agents in the treatment of ocular inflammation;
particularly, in patients with Behçet disease and JIA, for
whom anti-TNFα agents appear to be especially effective.
In 2016, EMA and FDA approved adalimumab for
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treating non‑infectious intermediate, posterior, and panu-
veitis in adult patients who have had an inadequate
response to corticosteroids, in patients in need of corticos-
teroid-sparing, or in whom corticosteroid treatment is
inappropriate. These biologics are administered parenter-
ally with intervals ranging from twice a week to every 8
weeks depending on the drug used. There are currently
five anti-TNFα agents available (Table 1).
Etanercept is a fusion protein combining two human
p75 TNFα receptors extracellular fractions fused to the
human Fc portion of IgG1 in order to prolong the half-
life. There are substantial data suggesting that etanercept
has lower efficacy for treatment of uveitis than anti-TNFα
antibodies.30 It could be explained by the fact that, while
both infliximab and adalimumab bind effectively to the
soluble and transmembrane forms of TNFα, etanercept
forms less stable bonds with TNFα, particularly the trans-
membrane form.31 Infliximab is amurine-human chimeric
antibody against TNFα and adalimumab is a fully human
monoclonal antibody targeting TNFα. Recently, strong
recommendationsweremade to explain that adalimumab
and infliximab should be considered as first-line immu-
nomodulatory agents for severe uveitis associated with
Behçet disease; and as second-line immunomodulatory
agents for the treatment of uveitis associated with JIA
and for the treatment of severe posterior uveitis or panu-
veitis, who failed or are not candidate to immunomodula-
tion with antimetabolite or calcineurin inhibitor.30
The most recently approved agents, golimumab and
certolizumab pegol, have been used for a shorter period in
ocular inflammatory conditions. Golimumab is a fully
human anti-TNFα monoclonal antibody. The constant
regions of the heavy and light chains of golimumab are
identical to those of infliximab in terms of the amino acid
sequence. Since 2011, several case reports and series
demonstrated successful control of severe uveitis with
golimumab, especially in JIA and Behçet disease.32–36
Certolizumab pegol consists of a PEGylated recombinant
humanized antibody Fab fragment against TNFα.
Pegylation of the antibody delays the elimination.
Current evidence indicates that certolizumab pegol is an
effective option for the treatment of axSpA and PsA.37,38
The reported experience on the use of certolizumab pegol
for treatment of immune-mediated uveitis is currently
limited to one retrospective case series (see below).39
Adverse Events
Anti-TNFα agents carry a specifically increased risk of
tuberculosis (TB), usually reactivations of latent disease40
but also primary infection. Important differences in the
risk of latent TB reactivation exist, with the risk being
higher with infliximab and adalimumab than with
etanercept.41,42 A recent study showed that tuberculosis
incidence rates during infliximab and adalimumab treat-
ment were 2.78 and 3.88 times, respectively, higher than
during etanercept treatment in patients with rheumatoid
arthritis.43 Screening for latent tuberculosis and prophy-
lactic anti-TB treatment for all those found positive is
recommended for all patients planning to start therapy
with anti-TNFα agents. Various and severe non-tubercu-
lous opportunistic infections, especially those with intra-
cellular microorganisms, may develop in patients
receiving anti-TNFα treatment. Several demyelinating
and neurologic events, including exacerbations of pre-
existing multiple sclerosis, were reported in patients
receiving anti-TNFα agents.44–48 There is no conclusive
evidence for an increase in risk of solid tumors or lympho-
proliferative diseases with anti-TNFα agents,49,50 except
TABLE 1. Anti-TNFα agents currently available.
Etanercept Infliximab Adalimumab Certolizumab pegol Golimumab
Year approved for use in the USA 1998 1999 2002 2008 2009
FDA and EMA-approved indications (2016)
Rheumatoid arthritis X X X X X
Juvenile idiopathic arthritis X X
Ankylosing spondylitis X X X X X
Psoriatic arthritis X X X X X
Plaque psoriasis X X X
Crohn disease (adult) X X Xa
Crohn disease (pediatric) X X
Ulcerative colitis X X X
Hidradenitis suppurativa X
Uveitis Xb
Route of administration SC IV SC SC SC
Usual posology in adults (mg) 50 3–5c 40 50 400
Usual maintenance dosing interval 1 week 8 weeks 2 weeks 1 month 1 month
IV, intravenous injection; SC, subcutaneous injection.
aIn 2016, certolizumab pegol had not yet been approved for the treatment of Crohn disease by EMA (European Medicines Agency).
bAdalimumab is indicated for the treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.
cmg/kg body weight.
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non-melanoma skin cancer for which anti-TNFα seems to
increase the risk.51 Development of antinuclear antibodies
and autoantibodies against double-stranded DNA has
previously been reported in response to all anti-TNFα
therapies, but may be more common with infliximab.
However, “full-blown” anti-TNF-induced lupus or vascu-
litis are rare.52 Mechanisms involved in the production of
antinuclear antibodies are still unknown.53 Anti-TNFα
may lead to apoptotic cell death and the release of auto-
antigens that induce antiDNA antibodies in susceptible
patients.54,55 Downregulation of TNFαmay be associated
with autoantibody production due to the upregulation of
IL-10, which activates autoreactive B cells.53 Local compli-
cations at the site of drug administration have been fre-
quently reported. Anti-TNFα agents can induce the
formation of neutralizing antibodies, resulting in loss of
efficacy and the appearance of infusion reactions.56 New
onset andworsening of congestive heart failure have been
reported.49 A rare and paradoxical adverse event is devel-
opment of sarcoidosis during anti-TNFα therapy,57–60 as
well as paradoxical occurrence of psoriasis.61
The issue of whether anti-TNFα agents cause ocular
inflammation remains debated.62 There are several case
reports of uveitis developing in patients treated with anti-
TNFα therapy. Most cases have been reported with
etanercept.63–69 However, as etanercept was shown to be
less effective than anti-TNFα antibodies to prevent and to
control uveitis, does it induce uveitis or does it only fail to
prevent their occurrence? Nonetheless, Lim et al. reported
26 cases of uveitis presumably associated with anti-TNFα,
in which no known condition predisposing to uveitis was
identified.62 However, the authors conceded that there
was limited information on the clinical diagnoses
available.
Anti-TNFα Agents for Acute HLA-B27 Uveitis
Attack
Actually, in acute HLA-B27-associated uveitis, topical or
periocular corticosteroids and mydriatic agents can man-
age most acute attacks. Nevertheless, oral administration
of corticosteroids may be required in cases of recalcitrant
inflammation. However, in some patients, steroids use is
restricted owing to a lack of response, intolerance, or side-
effects. In these situations, infliximab may be effective in
treating an acute uveitis attack.70–72 El-Shabrawi and
Hermann described a prospective non-comparative case
series of seven consecutive patients with acute onset of
HLA-B27-associated anterior uveitis who received a sin-
gle infliximab infusion of 10 mg/kg body weight. Total
resolution of the uveitis was achieved with infliximab as
the sole anti-inflammatory drug in all but one patient. The
median duration of uveitis was 8 ± 12 days. A relapsewas
seen in four patients after a median period of 5 ± 6.4
months.72 Rudwaleit et al. reported, in patientswith active
AS during adalimumab treatment, that the rate of anterior
uveitis flares was reduced by 50% in 28 patients with
symptomatic anterior uveitis at baseline (p = 0.001) and
by 45% in 43 patients with chronic uveitis (p = 0.002).73
Use of golimumab in a case of refractory HLA-B27
uveitis was recently reported74 and Faez et al. showed
that golimumab may be useful for uveitis associated
with SpA (three patients).75 Moreover, golimumab effi-
cacy was noted in three out of four patients with HLA-
B27 uveitis, who had inadequate response to previous
biologics.35 Golimumab therapy achieved complete
control of inflammation in 12/13 patients (92.3%)
after 6 months of treatment in a retrospective study,
including patients with PsA (two patients) or AS (two
patients).76 More recently, a multicenter study
reported in EULAR (European League Against
Rheumatism) Congress 2015 showed that golimumab
seemed to be effective and safe in refractory uveitis
associated with AS.77 In this retrospective study, after
a mean follow-up of 13 months, 7/9 patients were on
remission.
The reported experience on the use of certolizumab
pegol for treatment of immune-mediated uveitis is cur-
rently limited to one retrospective case series. Seven
patients with infliximab and adalimumab refractory
and/or intolerant uveitis were treated and five patients
achieved quiescence. Four out of the seven patients pre-
sented uveitis associatedwith AS or PsA and two patients
showed only a partial response.39 However, data is too
limited to make any substantial comments regarding this
agent in HLA-B27-associated uveitis treatment.
As a result, expert panel recommendations published
in 2014 concerning spondyloarthritis or HLA-B27-asso-
ciated uveitis explained that infliximab or adalimumab
may be used as corticosteroid-sparing treatment for
patients with chronic uveitis resulting from
spondyloarthritis.30
Anti-TNFα Agents in Preventing HLA-B27
Uveitis Relapses
The main interest of anti-TNFα agents concerning HLA-
B27-associated uveitis lies in preventing relapses of uvei-
tis. A large retrospective study suggested that infliximab
and adalimumab reduced the rate of uveitis, while the
frequency of uveitis in patients with spondyloarthritis
treated with etanercept remained unchanged.78 In a
large meta-analysis, concerning data from four placebo-
controlled studies with anti-TNF agents in AS (two with
etanercept and two with infliximab) and three open-label
studies, infliximab and etanercept therapies seem to
reduce the incidence of uveitis versus placebo (6.8 per
100 patient-years and 15.6 per 100 patient-years, respec-
tively). Furthermore, infliximab appeared to be more
effective than etanercept, even though the difference
between them did not reach statistical significance (3.4
per 100 patient-years and 7.9 per 100 patient-years, respec-
tively) (p = 0.08).79
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Similarly, adalimumab was evaluated from data of
1250 patients with active AS in a prospective open-label
study. The anterior uveitis flare rates before adalimumab
treatment were 15 per 100 patient-years. Adalimumab
achieved an approximately 50% reduction in uveitis
flares.73 Finally, a recent cohort study about 2115 patients
indicated that initial adalimumab therapy is associated
with a significantly lower risk of developing uveitis com-
pared to initial etanercept therapy in anti-TNF-naive
patients diagnosed with AS and no prior history of
uveitis.80,81
Furthermore, an open-label, phase IV study investigat-
ing the difference in the annual incidence rate of uveitis
attacks in participants with AS before treatment and after
treatment with golimumab is underway (https://clinical
trials.gov; NCT01668004). Finally, a recent study sug-
gested that certolizumabpegol had an impact on reducing
uveitis flares in axial spondyloarthritis. However, the
number of patients experiencing uveitis flares was low
and there was an imbalance in the number of patients
with prior history of uveitis between the placebo and the
certolizumab pegol group. Prospective studies are man-
datory to confirm or to invalidate these findings.82
Hence, the use of infliximab or adalimumab should be
considered first rather than using a soluble TNF receptor,
in “spondyloarthritis patients” with a history of uveitis,
although there are no prospective head-to-head studies.
Furthermore, given collective clinical experience in uveitis
and other conditions, switching between anti-TNFα thera-
pies appears to be efficient and safe in cases of primary or
secondary failure permitting to prolong their use.83
It is however necessary to note that a meta-analysis
published by Wu et al.84 from six selected randomized
controlled trials38,85–88 shows contradictory results. In this
study, 663 patients “etanercept vs placebo” and 436
patients “monoclonal anti-TNFα antibodies vs placebo”
were analyzed. Subgroup analysis showed TNFα receptor
fusion proteins to be more efficacious than placebo (p =
0.04); whereas monoclonal anti-TNFα antibodies did not
significantly differ from placebo. These surprising results
compared with previously published studies might be
explained by the fact that only randomized controlled
trials,with a short follow-up (range: 12–30weeks) limiting
the number of “uveitis events”, were analyzed. It is also
important to note that the absence of systematic ophthal-
mologic evaluation, and the analysis of a study involving
certolizumab for which intraocular penetration might be
modified due to the addition of a macromolecule to
increase its half-life may partly explain the
discrepancies.38
Non-anti-TNF Biologic Modifier Drugs and
HLA-B27-associated Uveitis
TNFα inhibitors have dramatically improved the treat-
ment of SpA patients. However, as up to 40% of patients
do not respond well to anti-TNFα treatment, either due to
adverse reactions and intolerance or due to inefficacy,
there is still a need for other and better therapeutic
compounds.89 Are these newmolecules going to be effec-
tive on treatment and prevention of uveitis flares? Only
very fewdata regardingHLA-B27-associateduveitisman-
agement with other biologic agents are available.
Anti-interleukins (IL)
Anti-interleukins therapies, which could be used in uvei-
tis, are summarized in Table 2. The major interest has
recently focused on therapies targeting the IL-23/IL-17
axis, as there is an extensive rationale for targeting this
pathway in SpA. First, abnormal withdrawal of the
molecule HLA-B27, which cannot migrate correctly and
stays in the endoplasmic reticulum, may lead to an
inflammatory answer (production of IL-23). Second, cell
surface HLA-B27 homodimers may induce stimulation
of the innate immunity. These homodimers can interact
with KIR3DL2 (killer-cell-Ig-like receptor), expressed by
natural killer cells and a minority of lymphocytes T. The
rate of cells TCD4 + KIR3DL2 is increased in the blood of
the subjects SpA-B27+. These cells, after interaction with
HLA-B27 homodimers, produce high quantities of IL-
17.89,90 Third, plasma IL-17 levels are high in patients
with AS but not in healthy controls or in patients with
rheumatoid arthritis. IL-17 levels in joint fluid are higher
in reactive arthritis and undifferentiated spondyloarthri-
tis than in rheumatoid arthritis.91 Furthermore, several
data suggest that IL-17 is implicated in the pathogenesis
of uveitis. Indeed, serum IL-17A levels were found to be
elevated in uveitis patients, particularly in active
patients,92 and increased IL-17A transcript was detected
in retinas of mice during experimental autoimmune
uveoretinitis.93
Anti-interleukin-17 Therapy
Secukinumab is a fully humanized, anti-IL-17A monoclo-
nal antibody. Secukinumab reduced clinical or biologic
signs of active AS and psoriatic arthritis in phase III
studies.94 There are no reports on its use in HLA-B27-
associated uveitis management at present. A prospective
study showed its efficiency in the treatment of non-infec-
tious uveitis in 13 out of 16 patients (intravenous
secukinumab);95 however, its efficacy was not confirmed
in three clinical trials assessing subcutaneous secukinu-
mab against placebo in management of uveitis associated
with Behçet disease and other non-infectious uveitis
(unknown HLA-B27 status).96 In contrast, intravenous
secukinumab was reported to be effective and well-toler-
ated in patients with non-infectious uveitis (unknown
HLA-B27 status) who required systemic corticosteroid-
sparing immunosuppressive therapy.97
Anti-interleukin-12/23 Therapy
Ustekinumab is a fully humanized monoclonal anti-
body with high affinity for the common p40 subunits
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of IL-12 and IL-23. There are no reports on its use in
HLA-B27-associated uveitis management at present.
Recent studies reported a beneficial effect of ustekinu-
mab in the treatment of PsA and axial disease in AS
patients.98–101
Other Anti-interleukin Therapy
Biologic therapies targeting several key proinflamma-
tory cytokines, such as blockade of IL-1 with anakinra-
102,103 and inhibition of IL-6 with both tocilizumab and
sarilumab (human monoclonal antibody against the
interleukin-6 receptor), failed to show clinical efficacy
in AS.104,105 Uveitis flares are not detailed in these
studies. On the contrary, tocilizumab was reported
with success in case reports and case series about
management of refractory uveitis associated with JIA,
birdshot retinochoroidopathy, Behçet disease-asso-
ciated uveitis and idiopathic panuveitis.106–112
Interestingly, among these studies, only one patient
with an associated spondyloarthritis and panuveitis
was successfully treated (HLA-B27-positive).107 On
the contrary, Wendling et al. reported a first episode
of uveitis in a patient being treated for HLA-B27-posi-
tive AS.113
Other Molecules
cT-cell and B-cell targeted therapies, such as Rituximab
(CD20-directed cytolytic antibody)114 and Abatacept
(soluble fusion protein able to block CD-80 and CD-
86 present on antigen- presenting cells),115,116 only
showed modest, if any, therapeutic efficacy in SpA.
T-cell and B-cell targeting therapies failure might be
consistent with the concept that SpA belongs to the
class of autoinflammatory rather than autoimmune
disorders.117 No data are available concerning possible
associated uveitis in these studies.
DISCUSSION
The treatment of extra-articular manifestations asso-
ciated with HLA-B27 has undergone a complete revo-
lution in the past two decades, mainly as a
consequence of the introduction of biologic therapies
and principally anti-TNFα agents. The current data on
the use of biologics in the management of uveitis
associated with HLA-B27 are relatively restricted and
most of the available data concentrate on the preven-
tion of uveitis flares. Even though, there are no pro-
spective head-to-head randomized comparative
studies comparing efficacy of anti-TNFα agents in
HLA-B27 uveitis management, infliximab and adali-
mumab are generally accepted to be more effective
than etanercept. Because golimumab requires less fre-
quent injections, it might have potential application in
uveitis as well. When patients become refractory to
treatment with anti-TNFα agents, or when there is a
formal contraindication for their use, there is a need
for the use of new therapeutic options, targeting other
cytokines or their proinflammatory pathways. Only
very few data are available with other biologic agents,
but data from other immune-mediated inflammatory
diseases keep a promise for non-infectious inflamma-
tory ocular diseases.
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